Tolerance toxicity

Radioimmunotherapy is generally well tolerated. Toxicities include infusion-related reactions, myelosuppression, and possibly myelodysplastic syndrome or AML. 131I-tositumomab can cause thyroid dysfunction. 

Kleinerman, E.S. et al., Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide Tolerability, toxicity, and immune stimulation, J. Immunother. Emphasis. Tumor Immunol., 17, 181, 1995. 

Specific (local tissue tolerance) toxicity studies may be necessary due to special characteristics of the product or the clinical indication. Adjuvanted vaccines are routinely evaluated for local (injection site) reactions, and cellular therapies are routinely screened for tumorigenic potential. Research is also needed to better predict the sensitizing potential of biological products and to determine the relevance of serum antibody levels following repeat dosing in animals and humans. 

Unfortunately, the public perception of such concepts as safety, risk, hazard, tolerance, toxicity, etc. are notoriously inconsistent in that the... 

Other potential radiation sensitizers for cervical cancer are being explored in phase I and II trials. Paclitaxel has been combined with cisplatin in several small phase I studies. Pignata et al. (29) found that 50 mg/m2 per week of paclitaxel could be combined with weekly cisplatin (30 mg/m2) and radiation therapy with acceptable toxicity, although 10 of 18 patients in their study had grade 3-4 hematologic toxicity. Chen etal. (30) also were able to give weekly paclitaxel at a dose of 50 mg/m2 (in this case combined with 50 mg/m2 of cisplatin every three weeks) with tolerable toxicity and minimal delay in planned radiation therapy. In both studies, the dose-limiting side effect appeared to be diarrhea. It should be noted that the total dose of cisplatin delivered in these trials was lower than that used in the most successful prospective trials of cisplatin or cisplatin and fluorouracil (Table 3). 

Catalyst deactivation is often characterized through empirical parameters. Some authors (refs, 5-8) have used parameters like tolerance, toxicity, susceptibility or initial deactivation which are directly obtained from the experimental deactivation curves. In other cases (refs. 9-11), experimentally found deactivation equations have been employed as an approximation of the actual deactivation law (linear, hyperbolic, exponential or power equations). While the use of such a kind of parameters provide useful information on the catalyst sensitivity to a given poison, the approach of obtaining the deactiv-... 

In toxicology, the term resistance may be defined as an inherent genetic capability of an organism to oppose any adverse effects, manifest in either potency or dose, of a toxicant. Others have defined resistance as the ability of an organism to tolerate toxic doses of a substance that would be lethal to most in a normal population of the same species. It is important to distinguish the phenomenon of resistance from tolerance, which is the ability of an organism to adapt to the adverse effects of a toxicant with each successive dose of that toxicant. Resistance can also... 

Normally, one would fix the level of tolerable toxicity and maximize the effectiveness under that constraint. However, setting the tolerable level of toxicity is related to the individual s current state of health. Under certain conditions, setting such thresholds could be exceptionally challenging for the health practitioners. 

Catalyst deactivation is often characterized through empirical parameters. Some authors (refs. 5-8) have used parameters like tolerance, toxicity, susceptibility or initial deactivation which are directly obtained from the... 

In addition to the resistance development, the use of Pis in the clinics is further affected by their tolerability, toxicity, and adverse effects. The Pis often interfere with lipid metabolism and trafficking pathways. The side effects might decrease the willingness of patients to undergo treatment and thus contribute indirectly to the evolution of resistance. Therefore, the need for development of novel Pis with broad specificity against Pl-resistant HIV mutants, better pharmacokinetic properties, lower toxicity, and simple dosage is still very urgent. 

Toxltolerant Tolerates toxic and xenobiotic chemicals like benzene... 

---